This review synthesizes basic science and translational evidence supporting glucagon-like peptide-1, glucagon-like peptide-2, and dipeptidyl peptidase-IV inhibition as emerging therapeutic concepts in inflammatory bowel disease
GLP-1 medications may affect gut function, appetite signaling, and metabolic health, but also have clear limitations
They looked at two groups: Group A included over 38,000 patients who had taken GLP-1 medications at least twice
Infused with botanical oils and extracts
There are review articles, there are letters, there is one paper that was retracted at its own authors request
These side effects are transient and typically subside within a day or two following injection